Viking Therapeutics started at neutral by Citi
Citi has initiated coverage of Viking Therapeutics (NASDAQ:VKTX) with a neutral rating, citing the need for more data for its weight-loss drug candidate VK2735 and high barriers to entry. The ...
Investor's Business Daily on MSN35m
Neurocrine Crumbles On Lackluster Guidance For Its Bread-And-Butter Drug
Neurocrine stock crashed to a three-month low Friday after the company's bread-and-butter drug and its guidance for 2025 both lagged Wall Street's expectations.The company is best known for its drug, ...